Cargando…

DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials

Detalles Bibliográficos
Autores principales:	Morgan, C, Jin, X, Yu, X, De Rosa, S, Kublin, J, Metch, B, Keefer, M, NIAID, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441823/ http://dx.doi.org/10.1186/1742-4690-9-S2-P133

Ejemplares similares

Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men
por: Moodie, Zoe, et al.
Publicado: (2015)

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials
por: Huang, Yunda, et al.
Publicado: (2015)

P14-02. Social impact events in Phambili, the first phase 2B HIV vaccine trial in South Africa
por: Allen, MA, et al.
Publicado: (2009)

HIV vaccines beyond COVID‐19: merits of trust
por: Kublin, James G
Publicado: (2021)

P14-07. Offering new prevention modalities in HIV vaccine trials: experience with male circumcision in the Phambili trial
por: de Bruyn, G, et al.
Publicado: (2009)

Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults
por: Kalams, Spyros A., et al.
Publicado: (2012)

Do circulating HIV vaccine plasmids contribute to immunogenicity in humans?
por: Wahren, B, et al.
Publicado: (2006)

Feasibility of recruiting high-risk women in the US for HIV vaccine efficacy trials (HVTN 906)
por: Koblin, B, et al.
Publicado: (2012)

Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models
por: Dimitrov, Dobromir, et al.
Publicado: (2015)

House Ball Community Leaders’ Perceptions of HIV and HIV Vaccine Research
por: Alio, Amina P., et al.
Publicado: (2020)

Gender aspects on HIV prevention efforts and participation in HIV vaccine trials among Police officers in Dar es Salaam, Tanzania
por: Tarimo, Edith A. M., et al.
Publicado: (2018)

Competing biomedical HIV prevention strategies: potential cost‐effectiveness of HIV vaccines and PrEP in Seattle, WA
por: Adamson, Blythe, et al.
Publicado: (2019)

Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination
por: Cram, Jacob A., et al.
Publicado: (2019)

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection
por: Ditse, Zanele, et al.
Publicado: (2020)

Attracting, equipping and retaining young medical doctors in HIV vaccine science in South Africa
por: Flood, Danna, et al.
Publicado: (2015)

The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States
por: Adamson, Blythe J. S., et al.
Publicado: (2017)

New HIV peptide-based immunoassay resolves vaccine-induced seropositivity in HIV vaccine (Phase III) trial participants
por: Penezina, O, et al.
Publicado: (2012)

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials
por: Moodie, Zoe, et al.
Publicado: (2020)

Willingness to Participate in HIV Therapeutic Vaccine Trials among HIV-Infected Patients on ART in China
por: Dong, Yuan, et al.
Publicado: (2014)

The Influence of Community Members on Participation by Youth in an HIV Vaccine Trial in Tanzania
por: Mbunda, Theodora, et al.
Publicado: (2016)

Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya
por: Nyaoke, Borna A., et al.
Publicado: (2017)

Under consent: participation of people with HIV in an Ebola vaccine trial in Canada
por: David, Pierre-Marie, et al.
Publicado: (2021)

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials
por: Fischinger, Stephanie, et al.
Publicado: (2021)

Risk Factors Associated with HIV Acquisition in Males Participating in HIV Vaccine Efficacy Trials in South Africa
por: Malahleha, Mookho, et al.
Publicado: (2023)

Modeling HIV Vaccines in Brazil: Assessing the Impact of a Future HIV Vaccine on Reducing New Infections, Mortality and Number of People Receiving ARV
por: Fonseca, Maria Goretti P., et al.
Publicado: (2010)

Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study
por: de Montigny, Simon, et al.
Publicado: (2018)

Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses
por: Hopkins, Kathryn L., et al.
Publicado: (2014)

P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?
por: Gray, GE, et al.
Publicado: (2009)

Multi-trial analysis of HIV-1 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines
por: Mayer-Blackwell, Koshlan, et al.
Publicado: (2022)

Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial
por: Mpofu, Rephaim, et al.
Publicado: (2021)

Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP(®) DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults
por: Edupuganti, Srilatha, et al.
Publicado: (2020)

Correction: Modeling HIV Vaccines in Brazil: Assessing the Impact of a Future HIV Vaccine on Reducing New Infections, Mortality and Number of People Receiving ARV
por: Fonseca, Maria Goretti P., et al.
Publicado: (2010)

Correction to: Under consent: participation of people with HIV in an Ebola vaccine trial in Canada
por: David, Pierre-Marie, et al.
Publicado: (2021)

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk
por: Andersen-Nissen, Erica, et al.
Publicado: (2021)

Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature
por: Palli, Rohith, et al.
Publicado: (2020)

HIV prevention by vaccine
por: Gallo, Robert
Publicado: (2012)

The HIV vaccine saga
por: Smith, Kendall A
Publicado: (2003)

Prospecting for an HIV vaccine
por: Brett-Major, D. M., et al.
Publicado: (2017)

Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial
por: Koblin, Beryl A., et al.
Publicado: (2011)

Conserved HIV Epitopes for an Effective HIV Vaccine
por: Sahay, Bikash, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2ckhuf3bipc1rhsmlp4u3pgc67